Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $552.80 million. The enterprise value is $523.00 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 91.37 million shares outstanding. The number of shares has decreased by -11.33% in one year.
| Current Share Class | 91.37M |
| Shares Outstanding | 91.37M |
| Shares Change (YoY) | -11.33% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 6.66% |
| Owned by Institutions (%) | 3.74% |
| Float | 21.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.89 |
| Forward PS | 6.21 |
| PB Ratio | 5.64 |
| P/TBV Ratio | 5.92 |
| P/FCF Ratio | 186.13 |
| P/OCF Ratio | 132.44 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 103.10, with an EV/FCF ratio of 170.19.
| EV / Earnings | n/a |
| EV / Sales | 4.47 |
| EV / EBITDA | 103.10 |
| EV / EBIT | 216.47 |
| EV / FCF | 170.19 |
Financial Position
The company has a current ratio of 4.64, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.64 |
| Quick Ratio | 3.68 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.27 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -3.08% and return on invested capital (ROIC) is -17.79%.
| Return on Equity (ROE) | -3.08% |
| Return on Assets (ROA) | 1.03% |
| Return on Invested Capital (ROIC) | -17.79% |
| Return on Capital Employed (ROCE) | 1.70% |
| Weighted Average Cost of Capital (WACC) | 33.24% |
| Revenue Per Employee | $187,278 |
| Profits Per Employee | -$10,179 |
| Employee Count | 625 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.60 |
Taxes
In the past 12 months, GYRE has paid $4.28 million in taxes.
| Income Tax | 4.28M |
| Effective Tax Rate | 758.16% |
Stock Price Statistics
The stock price has decreased by -44.85% in the last 52 weeks. The beta is 5.28, so GYRE's price volatility has been higher than the market average.
| Beta (5Y) | 5.28 |
| 52-Week Price Change | -44.85% |
| 50-Day Moving Average | 7.38 |
| 200-Day Moving Average | 7.67 |
| Relative Strength Index (RSI) | 33.64 |
| Average Volume (20 Days) | 73,880 |
Short Selling Information
The latest short interest is 1.58 million, so 1.73% of the outstanding shares have been sold short.
| Short Interest | 1.58M |
| Short Previous Month | 1.58M |
| Short % of Shares Out | 1.73% |
| Short % of Float | 7.43% |
| Short Ratio (days to cover) | 26.88 |
Income Statement
In the last 12 months, GYRE had revenue of $117.05 million and -$6.36 million in losses. Loss per share was -$0.08.
| Revenue | 117.05M |
| Gross Profit | 111.30M |
| Operating Income | 2.42M |
| Pretax Income | 564,000 |
| Net Income | -6.36M |
| EBITDA | 5.07M |
| EBIT | 2.42M |
| Loss Per Share | -$0.08 |
Full Income StatementBalance Sheet
The company has $49.81 million in cash and $823,000 in debt, with a net cash position of $48.99 million or $0.54 per share.
| Cash & Cash Equivalents | 49.81M |
| Total Debt | 823,000 |
| Net Cash | 48.99M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 136.99M |
| Book Value Per Share | 1.11 |
| Working Capital | 71.94M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $4.32 million and capital expenditures -$1.25 million, giving a free cash flow of $3.07 million.
| Operating Cash Flow | 4.32M |
| Capital Expenditures | -1.25M |
| Depreciation & Amortization | 2.66M |
| Net Borrowing | n/a |
| Free Cash Flow | 3.07M |
| FCF Per Share | $0.03 |
Full Cash Flow StatementMargins
Gross margin is 95.09%, with operating and profit margins of 2.06% and -5.44%.
| Gross Margin | 95.09% |
| Operating Margin | 2.06% |
| Pretax Margin | 0.48% |
| Profit Margin | -5.44% |
| EBITDA Margin | 4.33% |
| EBIT Margin | 2.06% |
| FCF Margin | 2.63% |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 11.33% |
| Shareholder Yield | 11.33% |
| Earnings Yield | -1.11% |
| FCF Yield | 0.54% |
Analyst Forecast
The average price target for GYRE is $18.67, which is 208.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.67 |
| Price Target Difference | 208.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 19.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GYRE has an Altman Z-Score of 18 and a Piotroski F-Score of 5.
| Altman Z-Score | 18 |
| Piotroski F-Score | 5 |
